Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population.
作者信息
Buti S, Puligandla M, Bersanelli M, DiPaola R S, Manola J, Taguchi S, Haas N B
出版信息
Ann Oncol. 2018 Jul 1;29(7):1604. doi: 10.1093/annonc/mdx799.
Abstract
摘要
相似文献
1
Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population.一种用于轻松预测肾细胞癌预后的新模型的验证：应用于ASSURE试验人群的GRANT评分
Ann Oncol. 2018 Jul 1;29(7):1604. doi: 10.1093/annonc/mdx799.
2
Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation.预测肾癌复发：前瞻性临床试验验证现有预后模型的局限性。
J Clin Oncol. 2019 Aug 10;37(23):2062-2071. doi: 10.1200/JCO.19.00107. Epub 2019 Jun 19.
3
Author Correction: Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients.作者更正：监测、流行病学和最终结果（SEER）数据库中分级、年龄、淋巴结和肿瘤（GRANT）评分的验证：一种预测接受手术治疗的肾细胞癌患者生存率的新工具。
Sci Rep. 2020 Feb 5;10(1):2304. doi: 10.1038/s41598-020-59358-9.
4
Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score.基于术前血清C反应蛋白和TNM分类的肾切除术治疗透明细胞肾细胞癌患者新结局预测模型的开发与外部验证：TNM-C评分
J Urol. 2009 Mar;181(3):1004-12; discussion 1012. doi: 10.1016/j.juro.2008.10.156. Epub 2009 Jan 16.
5
Validation by calibration of the UCLA integrated staging system prognostic model for nonmetastatic renal cell carcinoma after nephrectomy.通过校准对肾切除术后非转移性肾细胞癌的加州大学洛杉矶分校综合分期系统预后模型进行验证。
Cancer. 2008 Jul 1;113(1):65-71. doi: 10.1002/cncr.23517.
6
Prevalence and prognostic value of FBXO11 expression in patients with clear cell renal cell carcinoma.FBXO11 表达在透明细胞肾细胞癌患者中的流行率和预后价值。
BMC Cancer. 2019 Jun 3;19(1):534. doi: 10.1186/s12885-019-5736-8.
7
Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma.一种用于肝细胞癌患者的新预后系统的开发与验证
PLoS Med. 2016 Apr 26;13(4):e1002006. doi: 10.1371/journal.pmed.1002006. eCollection 2016 Apr.
8
A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies.一种用于预测局限性肾细胞癌手术后复发的 16 基因检测：开发和验证研究。
Lancet Oncol. 2015 Jun;16(6):676-85. doi: 10.1016/S1470-2045(15)70167-1. Epub 2015 May 12.
9
Interleukin-11 receptor predicts post-operative clinical outcome in patients with early-stage clear-cell renal cell carcinoma.白细胞介素-11 受体可预测早期透明细胞肾细胞癌患者的术后临床结局。
Jpn J Clin Oncol. 2015 Feb;45(2):202-9. doi: 10.1093/jjco/hyu194. Epub 2014 Nov 23.
10
Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).肾细胞癌肾切除术后 5 年以上复发相关特征：基于大型多中心数据库（CORONA/SATURN 项目）开发和内部验证预测晚期复发的风险模型（PRELANE 评分）。
Eur Urol. 2013 Sep;64(3):472-7. doi: 10.1016/j.eururo.2012.06.030. Epub 2012 Jun 22.
引用本文的文献
1
Patients with high nuclear grade pT1-ccRCC are more suitable for radical nephrectomy than partial nephrectomy: a multicenter retrospective study using propensity score.高核分级 pT1-ccRCC 患者更适合行根治性肾切除术而非部分肾切除术：基于倾向评分的多中心回顾性研究。
World J Surg Oncol. 2024 Jan 23;22(1):24. doi: 10.1186/s12957-024-03302-y.
2
Prognostic value of preoperative microscopic hematuria in patients with non-metastatic renal cell carcinoma who underwent nephrectomy.术前镜下血尿在接受肾切除术的非转移性肾细胞癌患者中的预后价值。
J Cancer Res Clin Oncol. 2023 Nov;149(15):13545-13552. doi: 10.1007/s00432-023-05204-0. Epub 2023 Jul 27.
Zotero 插件